1. Academic Validation
  2. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss

Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss

  • Ann Rheum Dis. 2016 Apr;75(4):721-9. doi: 10.1136/annrheumdis-2015-208093.
Akilan Krishnamurthy 1 Vijay Joshua 1 Aase Haj Hensvold 1 Tao Jin 2 Meng Sun 1 Nancy Vivar 1 A Jimmy Ytterberg 3 Marianne Engström 1 Cátia Fernandes-Cerqueira 1 Khaled Amara 1 Malin Magnusson 2 Gustaf Wigerblad 4 Jungo Kato 4 Juan Miguel Jiménez-Andrade 5 Kerry Tyson 6 Stephen Rapecki 6 Karin Lundberg 1 Sergiu-Bogdan Catrina 7 Per-Johan Jakobsson 1 Camilla Svensson 4 Vivianne Malmström 1 Lars Klareskog 1 Heidi Wähämaa 1 Anca I Catrina 1
Affiliations

Affiliations

  • 1 Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
  • 2 Department of Rheumatology and Inflammation Research, Institution of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • 3 Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
  • 4 Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
  • 5 UCB Unidad Académica Multidisciplinaria Reynosa Aztlán, Universidad Autónoma de Tamaulipas, Reynosa, Tamaulipas, México.
  • 6 UCB Pharma, Slough, UK.
  • 7 Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Abstract

Objectives: Rheumatoid arthritis (RA)-specific anti-citrullinated protein/peptide Antibodies (ACPAs) appear before disease onset and are associated with bone destruction. We aimed to dissect the role of ACPAs in osteoclast (OC) activation and to identify key cellular mediators in this process.

Methods: Polyclonal ACPA were isolated from the synovial fluid (SF) and peripheral blood of patients with RA. Monoclonal ACPAs were isolated from single SF B-cells of patients with RA. OCs were developed from blood cell precursors with or without ACPAs. We analysed expression of citrullinated targets and peptidylarginine deiminases (PAD) Enzymes by immunohistochemistry and cell supernatants by cytometric bead array. The effect of an anti-interleukin (IL)-8 neutralising antibody and a pan-PAD inhibitor was tested in the OC cultures. Monoclonal ACPAs were injected into mice and bone structure was analysed by micro-CT before and after CXCR1/2 blocking with reparixin.

Results: Protein citrullination by PADs is essential for OC differentiation. Polyclonal ACPAs enhance OC differentiation through a PAD-dependent IL-8-mediated autocrine loop that is completely abolished by IL-8 neutralisation. Some, but not all, human monoclonal ACPAs derived from single SF B-cells of patients with RA and exhibiting distinct epitope specificities promote OC differentiation in cell cultures. Transfer of the monoclonal ACPAs into mice induced bone loss that was completely reversed by the IL-8 Antagonist reparixin.

Conclusions: We provide novel insights into the key role of citrullination and PAD Enzymes during OC differentiation and ACPA-induced OC activation. Our findings suggest that IL8-dependent OC activation may constitute an early event in the initiation of the joint specific inflammation in ACPA-positive RA.

Keywords

Ant-CCP; Autoantibodies; Early Rheumatoid Arthritis.

Figures
Products